;PMID: 2779009
;source_file_1889.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..188] = [t:45..188]
;2)section:[e:192..274] = [t:192..274]
;3)section:[e:278..370] = [t:278..370]
;4)sentence:[e:374..551] = [t:374..551]
;5)sentence:[e:552..890] = [t:552..890]
;6)sentence:[e:891..988] = [t:891..988]
;7)sentence:[e:989..1085] = [t:989..1085]
;8)sentence:[e:1086..1402] = [t:1086..1402]
;9)sentence:[e:1403..1577] = [t:1403..1577]
;10)sentence:[e:1578..1755] = [t:1578..1755]
;11)section:[e:1759..1803] = [t:1759..1803]

;section 0 Span:0..39
;Jpn J Pharmacol. 1989 Aug;50(4):435-43.
(SEC
  (FRAG (NNP:[0..3] Jpn) (NNP:[4..5] J) (NNP:[6..15] Pharmacol) (.:[15..16] .)
        (CD:[17..21] 1989) (.:[22..29] Aug;50-LRB-) (CD:[29..30] 4)
        (-RRB-:[30..31] -RRB-) (CD:[31..38] :435-43) (.:[38..39] .)))

;sentence 1 Span:45..188
;Species and sex differences in the inhibitory action of the corticosteroid 
;alclometasone dipropionate on the hepatic drug-metabolizing system.
;[105..119]:substance:"corticosteroid"
;[121..147]:substance:"alclometasone dipropionate"
;[163..167]:substance:"drug"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[45..52] Species)
        (NML-1 (-NONE-:[52..52] *P*)))
      (CC:[53..56] and)
      (NP (NN:[57..60] sex)
        (NML-1 (NNS:[61..72] differences))))
    (PP (IN:[73..75] in)
      (NP
        (NP (DT:[76..79] the) (JJ:[80..90] inhibitory) (NN:[91..97] action))
        (PP (IN:[98..100] of)
          (NP
            (NP (DT:[101..104] the) (NN:[105..119] corticosteroid))
            (NP (NN:[121..134] alclometasone) (NN:[135..147] dipropionate))))
        (PP (IN:[148..150] on)
          (NP (DT:[151..154] the) (JJ:[155..162] hepatic)
            (ADJP (NN:[163..167] drug) (HYPH:[167..168] -)
                  (VBG:[168..180] metabolizing))
            (NN:[181..187] system)))))
    (.:[187..188] .)))

;section 2 Span:192..274
;Nishibe Y, Hamataka M, Hasegawa T, Ikeuchi J, Yoshizaki T, Touchi A,
;Matsubara  T.
(SEC
  (FRAG (NNP:[192..199] Nishibe) (NNP:[200..201] Y) (,:[201..202] ,)
        (NNP:[203..211] Hamataka) (NNP:[212..214] M,) (NNP:[215..223] Hasegawa)
        (NNP:[224..225] T) (,:[225..226] ,) (NNP:[227..234] Ikeuchi)
        (NNP:[235..237] J,) (NNP:[238..247] Yoshizaki) (NNP:[248..249] T)
        (,:[249..250] ,) (NNP:[251..257] Touchi) (NNP:[258..259] A)
        (,:[259..260] ,) (NNP:[261..270] Matsubara) (NNP:[272..274] T.)))

;section 3 Span:278..370
;Kanzakigawa Laboratory, Shionogi Research Laboratories, Shionogi & Co., Ltd.,
; Osaka, Japan.
(SEC
  (FRAG (NNP:[278..289] Kanzakigawa) (NNP:[290..300] Laboratory)
        (,:[300..301] ,) (NNP:[302..310] Shionogi) (NNP:[311..319] Research)
        (NNP:[320..332] Laboratories) (,:[332..333] ,) (NNP:[334..342] Shionogi)
        (CC:[343..344] &) (NNP:[345..348] Co.) (,:[348..349] ,)
        (NNP:[350..354] Ltd.) (,:[354..355] ,) (NNP:[357..362] Osaka)
        (,:[362..363] ,) (NNP:[364..369] Japan) (.:[369..370] .)))

;sentence 4 Span:374..551
;The effect of successive administration of the corticosteroid alclometasone 
;dipropionate (ACM) on the hepatic drug-metabolizing system was examined using
; male and female rats.
;[421..435]:substance:"corticosteroid"
;[436..463]:substance:"alclometasone  dipropionate"
;[465..468]:substance:"ACM"
;[485..489]:substance:"drug"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[374..377] The) (NN:[378..384] effect))
      (PP (IN:[385..387] of)
        (NP
          (NP (JJ:[388..398] successive) (NN:[399..413] administration))
          (PP (IN:[414..416] of)
            (NP
              (NP (DT:[417..420] the) (NN:[421..435] corticosteroid))
              (NP
                (NP (NN:[436..449] alclometasone) (NN:[451..463] dipropionate))
                (NP (-LRB-:[464..465] -LRB-) (NN:[465..468] ACM)
                    (-RRB-:[468..469] -RRB-)))))))
      (PP (IN:[470..472] on)
        (NP (DT:[473..476] the) (JJ:[477..484] hepatic)
          (ADJP (NN:[485..489] drug) (HYPH:[489..490] -)
                (VBG:[490..502] metabolizing))
          (NN:[503..509] system))))
    (VP (VBD:[510..513] was)
      (VP (VBN:[514..522] examined)
        (NP-2 (-NONE-:[522..522] *))
        (S-MNR
          (NP-SBJ (-NONE-:[522..522] *))
          (VP (VBG:[523..528] using)
            (NP
              (NP (JJ:[530..534] male)
                (NML-1 (-NONE-:[534..534] *P*)))
              (CC:[535..538] and)
              (NP (JJ:[539..545] female)
                (NML-1 (NNS:[546..550] rats))))))))
    (.:[550..551] .)))

;sentence 5 Span:552..890
;Although some pharmacological changes such as increases in  plasma enzyme
;activity, lipid level and protein concentration appeared similarly  in
;ACM-treated male and female rats, the activities of 7-alkoxycoumarin 
;O-dealkylase, especially the O-depropylation activity, decreased 
;dose-dependently by ACM administration only in male rats.
;[619..625]:substance:"enzyme"
;[636..641]:substance:"lipid"
;[652..659]:substance:"protein"
;[697..700]:substance:"ACM"
;[749..779]:substance:"7-alkoxycoumarin  O-dealkylase"
;[853..856]:substance:"ACM"
(SENT
  (S
    (SBAR-ADV (IN:[552..560] Although)
      (S
        (NP-SBJ
          (NP (DT:[561..565] some) (JJ:[566..581] pharmacological)
              (NNS:[582..589] changes))
          (PP (JJ:[590..594] such) (IN:[595..597] as)
            (NP
              (NP (NNS:[598..607] increases))
              (PP (IN:[608..610] in)
                (NP
                  (NP (NN:[612..618] plasma) (NN:[619..625] enzyme)
                      (NN:[626..634] activity))
                  (,:[634..635] ,)
                  (NP (NN:[636..641] lipid) (NN:[642..647] level))
                  (CC:[648..651] and)
                  (NP (NN:[652..659] protein) (NN:[660..673] concentration)))))))
        (VP (VBD:[674..682] appeared)
          (ADVP (RB:[683..692] similarly))
          (PP-LOC (IN:[694..696] in)
            (NP
              (NP
                (ADJP-1 (NN:[697..700] ACM) (HYPH:[700..701] -)
                        (VBN:[701..708] treated))
                (JJ:[709..713] male)
                (NML-2 (-NONE-:[713..713] *P*)))
              (CC:[714..717] and)
              (NP
                (ADJP-1 (-NONE-:[717..717] *P*))
                (JJ:[718..724] female)
                (NML-2 (NNS:[725..729] rats))))))))
    (,:[729..730] ,)
    (NP-SBJ
      (NP
        (NP (DT:[731..734] the) (NNS:[735..745] activities))
        (PP (IN:[746..748] of)
          (NP (NN:[749..765] 7-alkoxycoumarin) (NN:[767..779] O-dealkylase))))
      (,:[779..780] ,)
      (NP
        (ADVP (RB:[781..791] especially))
        (DT:[792..795] the) (NN:[796..811] O-depropylation)
         (NN:[812..820] activity)))
    (,:[820..821] ,)
    (VP (VBD:[822..831] decreased)
      (ADVP (NN:[833..837] dose) (HYPH:[837..838] -) (RB:[838..849] dependently))
      (PP (IN:[850..852] by)
        (NP (NN:[853..856] ACM) (NN:[857..871] administration)))
      (PP-LOC (RB:[872..876] only) (IN:[877..879] in)
        (NP (JJ:[880..884] male) (NNS:[885..889] rats))))
    (.:[889..890] .)))

;sentence 6 Span:891..988
;ACM did not affect the  hepatic drug-metabolizing activity in female rats and
;mice of both sexes.
;[891..894]:substance:"ACM"
;[923..927]:substance:"drug"
(SENT
  (S
    (NP-SBJ (NN:[891..894] ACM))
    (VP (VBD:[895..898] did) (RB:[899..902] not)
      (VP (VB:[903..909] affect)
        (NP (DT:[910..913] the) (JJ:[915..922] hepatic)
          (ADJP (NN:[923..927] drug) (HYPH:[927..928] -)
                (VBG:[928..940] metabolizing))
          (NN:[941..949] activity))
        (PP-LOC (IN:[950..952] in)
          (NP
            (NP (JJ:[953..959] female) (NNS:[960..964] rats))
            (CC:[965..968] and)
            (NP
              (NP (NNS:[969..973] mice))
              (PP (IN:[974..976] of)
                (NP (DT:[977..981] both) (NNS:[982..987] sexes))))))))
    (.:[987..988] .)))

;sentence 7 Span:989..1085
;Also,  ACM did not inhibit androgen-independent aniline hydroxylase activity
;even in  male rats.
;[996..999]:substance:"ACM"
;[1016..1024]:substance:"androgen"
;[1037..1056]:substance:"aniline hydroxylase"
(SENT
  (S
    (ADVP (RB:[989..993] Also))
    (,:[993..994] ,)
    (NP-SBJ (NN:[996..999] ACM))
    (VP (VBD:[1000..1003] did) (RB:[1004..1007] not)
      (VP (VB:[1008..1015] inhibit)
        (NP
          (ADJP (NN:[1016..1024] androgen) (HYPH:[1024..1025] -)
                (JJ:[1025..1036] independent))
           (NN:[1037..1044] aniline) (NN:[1045..1056] hydroxylase)
          (NN:[1057..1065] activity))
        (PP-LOC (RB:[1066..1070] even) (IN:[1071..1073] in)
          (NP (JJ:[1075..1079] male) (NNS:[1080..1084] rats)))))
    (.:[1084..1085] .)))

;sentence 8 Span:1086..1402
;The time course of changes of the drug-metabolizing system in male  rats
;showed a rapid decrease in cytochrome P-450 content and O-depropylation 
;activity following successive treatments with ACM, but there was a slow onset
;in  the decreases of the O-demethylation and O-deethylation activities of 
;7-alkoxycoumarin.
;[1120..1124]:substance:"drug"
;[1186..1202]:cyp450:"cytochrome P-450"
;[1278..1281]:substance:"ACM"
;[1385..1401]:substance:"7-alkoxycoumarin"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1086..1089] The) (NN:[1090..1094] time)
            (NN:[1095..1101] course))
        (PP (IN:[1102..1104] of)
          (NP
            (NP (NNS:[1105..1112] changes))
            (PP (IN:[1113..1115] of)
              (NP (DT:[1116..1119] the)
                (ADJP (NN:[1120..1124] drug) (HYPH:[1124..1125] -)
                      (VBG:[1125..1137] metabolizing))
                (NN:[1138..1144] system)))))
        (PP (IN:[1145..1147] in)
          (NP (JJ:[1148..1152] male) (NNS:[1154..1158] rats))))
      (VP (VBD:[1159..1165] showed)
        (NP
          (NP (DT:[1166..1167] a) (JJ:[1168..1173] rapid)
              (NN:[1174..1182] decrease))
          (PP (IN:[1183..1185] in)
            (NP
              (NP
                (NP
                  (NML (NN:[1186..1196] cytochrome) (NN:[1197..1202] P-450))
                  (NN:[1203..1210] content))
                (CC:[1211..1214] and)
                (NP (NN:[1215..1230] O-depropylation) (NN:[1232..1240] activity)))
              (VP (VBG:[1241..1250] following)
                (NP
                  (NP (JJ:[1251..1261] successive) (NNS:[1262..1272] treatments))
                  (PP (IN:[1273..1277] with)
                    (NP (NN:[1278..1281] ACM))))))))))
    (,:[1281..1282] ,) (CC:[1283..1286] but)
    (S
      (NP-SBJ (EX:[1287..1292] there))
      (VP (VBD:[1293..1296] was)
        (NP-PRD (DT:[1297..1298] a) (JJ:[1299..1303] slow)
                (NN:[1304..1309] onset))
        (PP (IN:[1310..1312] in)
          (NP
            (NP (DT:[1314..1317] the) (NNS:[1318..1327] decreases))
            (PP (IN:[1328..1330] of)
              (NP
                (NP (DT:[1331..1334] the)
                  (NML
                    (NML (NN:[1335..1350] O-demethylation)
                      (NML-1 (-NONE-:[1350..1350] *P*)))
                    (CC:[1351..1354] and)
                    (NML (NN:[1355..1369] O-deethylation)
                      (NML-1 (NNS:[1370..1380] activities)))))
                (PP (IN:[1381..1383] of)
                  (NP (NN:[1385..1401] 7-alkoxycoumarin)))))))))
    (.:[1401..1402] .)))

;sentence 9 Span:1403..1577
;When ACM was withdrawn, the O-demethylation and O-deethylation  activities
;rapidly returned to their control levels, while recovery of the 
;O-depropylation activity was slow.
;[1408..1411]:substance:"ACM"
(SENT
  (S
    (SBAR-TMP
      (WHADVP-3 (WRB:[1403..1407] When))
      (S
        (NP-SBJ-2 (NN:[1408..1411] ACM))
        (VP (VBD:[1412..1415] was)
          (VP (VBN:[1416..1425] withdrawn)
            (NP-2 (-NONE-:[1425..1425] *))
            (ADVP-TMP-3 (-NONE-:[1425..1425] *T*))))))
    (,:[1425..1426] ,)
    (NP-SBJ (DT:[1427..1430] the)
      (NML
        (NML (NN:[1431..1446] O-demethylation)
          (NML-1 (-NONE-:[1446..1446] *P*)))
        (CC:[1447..1450] and)
        (NML (NN:[1451..1465] O-deethylation)
          (NML-1 (NNS:[1467..1477] activities)))))
    (ADVP (RB:[1478..1485] rapidly))
    (VP (VBD:[1486..1494] returned)
      (PP (TO:[1495..1497] to)
        (NP (PRP$:[1498..1503] their) (NN:[1504..1511] control)
            (NNS:[1512..1518] levels)))
      (,:[1518..1519] ,)
      (SBAR-ADV (IN:[1520..1525] while)
        (S
          (NP-SBJ
            (NP (NN:[1526..1534] recovery))
            (PP (IN:[1535..1537] of)
              (NP (DT:[1538..1541] the) (NN:[1543..1558] O-depropylation)
                  (NN:[1559..1567] activity))))
          (VP (VBD:[1568..1571] was)
            (ADJP-PRD (JJ:[1572..1576] slow))))))
    (.:[1576..1577] .)))

;sentence 10 Span:1578..1755
;These results suggested that ACM inhibits the  hepatic drug-metabolizing
;enzyme activity associated with a specific form(s) of  androgen-dependent
;cytochrome P-450 in male rats.
;[1607..1610]:substance:"ACM"
;[1633..1637]:substance:"drug"
;[1651..1657]:cyp450:"enzyme"
;[1706..1714]:substance:"androgen"
;[1725..1741]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ (DT:[1578..1583] These) (NNS:[1584..1591] results))
    (VP (VBD:[1592..1601] suggested)
      (SBAR (IN:[1602..1606] that)
        (S
          (NP-SBJ (NN:[1607..1610] ACM))
          (VP (VBZ:[1611..1619] inhibits)
            (NP
              (NP (DT:[1620..1623] the) (JJ:[1625..1632] hepatic)
                (ADJP (NN:[1633..1637] drug) (HYPH:[1637..1638] -)
                      (VBG:[1638..1650] metabolizing))
                (NN:[1651..1657] enzyme) (NN:[1658..1666] activity))
              (VP (VBN:[1667..1677] associated)
                (NP (-NONE-:[1677..1677] *))
                (PP-CLR (IN:[1678..1682] with)
                  (NP
                    (NP (DT:[1683..1684] a) (JJ:[1685..1693] specific)
                        (NN:[1694..1701] form-LRB-s-RRB-))
                    (PP (IN:[1702..1704] of)
                      (NP
                        (ADJP (NN:[1706..1714] androgen) (HYPH:[1714..1715] -)
                              (JJ:[1715..1724] dependent))
                         (NN:[1725..1735] cytochrome) (NN:[1736..1741] P-450)))))))
            (PP-LOC (IN:[1742..1744] in)
              (NP (JJ:[1745..1749] male) (NNS:[1750..1754] rats)))))))
    (.:[1754..1755] .)))

;section 11 Span:1759..1803
;PMID: 2779009 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1759..1763] PMID) (::[1763..1764] :) (CD:[1765..1772] 2779009)
        (NN:[1773..1774] -LSB-) (NNP:[1774..1780] PubMed) (::[1781..1782] -)
        (NN:[1783..1790] indexed) (IN:[1791..1794] for)
        (NNP:[1795..1803] MEDLINE-RSB-)))
